Hidradenitis suppurativa at EADV 2022: Reimagining immunology to achieve a brighter future for patients
At the Novartis-sponsored hidradenitis suppurativa (HS) symposium ‘Hide & Seek’ at EADV 2022, experts covered a range of topics related to the management of HS and its impact on patients.
Dr Joslyn Kirby’s session focused on the patient, with Dr Barry McGrath providing insights into what it is like to live with hidradenitis suppurativa. Dr McGrath has lived with HS for over 30 years, and he openly shared his experience of the condition: from the frustrations of the delay in receiving a diagnosis, to its impacts on his life and the complexities in managing the condition in consultation with clinicians.
Dr Joslyn Kirby, Dr Philippe Guillem and Professor Christos C. Zouboulis then discussed the current state of HS management and future directions, with Professor Angelo Valerio Marzano moderating the session. This session highlighted European and North American treatment guidelines, when surgical options should be considered, and atypical lesions and severity assessment.
Watch video clips from the symposium to learn:
- What’s new in hidradenitis suppurativa
- Differences between the draft new European Guidelines and the North American Guidelines
- Strategies to connect with your patients
- When to consider surgery
The negative impacts of hidradenitis suppurativa on a person's life
Developed by EPG Health for Medthority. The following symposium has been developed by Novartis Pharma AG and expert faculty. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. FUSE ID: 246308